To discover, develop, and provide targeted medicines
to treat rare and neglected diseases,
particularly those of children.
Over 7000 rare diseases are known today. These collectively present a significant public health burden since 25 to 30 million patients are afflicted by these diseases in North America alone. Many of these are serious genetic diseases that strike young children. Neglected tropical diseases afflict nearly 1 billion people worldwide, with children making up over half of this patient population. These diseases are prevalent in less affluent countries, and trap families and children in unending cycle of poverty and suffering.
American MedChem Nonprofit Corporation (AMC) is committed to discover and develop small molecule-based medicines to treat children who suffer from rare or neglected diseases. These research efforts, in close partnership with our collaborators, will bring forward new drugs to cure these childhood diseases and improve the health and quality of life of children, their families and the community. Focused and experienced drug discovery research is crucial to create new medicines to treat children afflicted with these diseases for which effective therapies do not exist. Passionate AMC scientists expedite the path to breakthrough medicines through a systematic and high-quality translational drug discovery research approach that is focused on rare and neglected diseases of childhood.
AMC is a tax-exempt public charity under section 501 (c) (3) of the United States Internal Revenue Code. Our research laboratories are located in Salt Lake City, UT, USA.